Results 51 to 60 of about 159,192 (287)

Structural biology of ferritin nanocages

FEBS Letters, EarlyView.
Ferritin is a conserved iron‐storage protein that sequesters iron as a ferric mineral core within a nanocage, protecting cells from oxidative damage and maintaining iron homeostasis. This review discusses ferritin biology, structure, and function, and highlights recent cryo‐EM studies revealing mechanisms of ferritinophagy, cellular iron uptake, and ...
Eloise Mastrangelo, Flavio Di Pisa
wiley   +1 more source

Evaluation of complement components C3 and C4 in serum of patient with neoplastic diseases

مجلة علوم ذي قار, 2019
The aim of this study is to evaluate the level of complement components C3 and C4 in serum of cancer patients to find which activation pathway of the complment system has the more effect in these cases .
Zeenah weheed Atwan, Shereen Jawad Al-Ali, Mohamed Abbas Mehdy   +2 more
doaj   +4 more sources

Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features

Research and Practice in Thrombosis and Haemostasis, 2020
Background Complement may contribute to platelet destruction in immune thrombocytopenia (ITP), but serum complement levels of ITP patients are not well defined. This study characterized C3, C4, and CH50 levels from 108 ITP patients in comparison with 120
Abraham Z. Cheloff, David J. Kuter, Hanny Al‐Samkari   +2 more
doaj   +1 more source

Serum complements and immunoglobulin profiles in systemic lupus erythematosus patients: An observational study at a teaching hospital

Journal of Family Medicine and Primary Care, 2022
Context: Serum complement proteins and autoantibodies play an important role in the pathogenesis and diagnosis of systemic lupus erythematosus (SLE). Abnormalities in various immunoglobulin levels are described in patients of SLE.
Ranjan Singh Rana, Bitan Naik, Mahima Yadav, Usha Singh, Anup Singh, Shailja Singh   +5 more
doaj   +1 more source

Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment

Arthritis Care &Research, EarlyView.
Objective Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histologic features and treatment response.
Andrea Fava, Catriona A. Wagner, Carla J. Guthridge, Susan Macwana, Wade DeJager, Melissa E. Munroe, Peter Izmirly, H. Michael Belmont, Betty Diamond, Anne Davidson, Paul J. Utz, Michael H. Weisman, Philip M. Carlucci, Maria Dall'Era, Kenneth Kalunian, Chaim Putterman, Jennifer Anolik, Jennifer L. Barnas, David Wofsy, Diane Kamen, Richard A. Furie, Deepak A. Rao, the Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus Network, Chun‐Hao Lee, Derek Fine, Manny Monroy‐Trujillo, Ummara Shah, Mariko Ishimori, Robert M. Clancy, Michael Belmont, Ming Wu, Nicole Bornkamp, Evan Der, Beatrice Goilav, Nicole Jordan, Daniel Schwartz, James Pullman, David Wofsy, Dawn Smilek, Patti Tosta, Matthias Kretzler, Celine C. Berthier, E. Steve Woodle, Dave Hildeman, Michael Brenner, Michelle Petri, Joel M. Guthridge, Jill Buyon, Judith A. James   +48 more
wiley   +1 more source

Cell-bound complement activation products associate with lupus severity in SLE

Lupus Science and Medicine, 2020
Objectives To evaluate the association between lupus severity and cell-bound complement activation products (CB-CAPs) or low complement proteins C3 and C4.Methods All subjects (n=495) fulfilled the American College of Rheumatology (ACR) classification ...
Richard A Furie, Daniel J Wallace, Judith A James, Susan Manzi, Amit Saxena, Rosalind Ramsey-Goldman, Chaim Putterman, John Conklin, Anca Askanase, Jill P Buyon, Elena Massarotti, Roberta Vezza Alexander, Sonali Narain, Cristina Arriens, Kenneth C Kalunian, Christopher E Collins, Ghalib A Bello, Joseph Ahearn   +17 more
doaj   +1 more source

Structural Model for Factor X Inhibition of IgM and Complement-Mediated Neutralization of Adenovirus

Viruses, 2023
Adenovirus has strong therapeutic potential as an oncolytic virus and gene therapy vector. However, injecting human species C serotype 5 adenovirus, HAdv-C5, into the bloodstream leads to numerous interactions with plasma proteins that affect viral ...
Nicole Wagner, Dmitry M. Shayakhmetov, Phoebe L. Stewart   +2 more
doaj   +1 more source

The Renal Activity Index for Lupus Identifies Active Renal Disease and Treatment Response in Adult Patients With Systemic Lupus Erythematosus and Lupus Nephritis

Arthritis Care &Research, EarlyView.
Objective We evaluated the ability of the Renal Activity Index for Lupus (RAIL) to discriminate active lupus nephritis (LN) in adult patients with active systemic lupus erythematosus (SLE) and differentiate LN treatment response. Methods Urine samples from adults with biopsy‐proven active class III and IV LN from TULIP‐LN (active LN group ...
Hermine I. Brunner, Ellen M. Cody, Prasad Devarajan, Bin Huang, Chen Chen, Dominic Sinibaldi, Madhu Ramaswamy, Jacob Knagenhjelm, Frederick Jones, Philip Z. Brohawn, Raj Tummala, Catharina Lindholm, Wendy I. White   +12 more
wiley   +1 more source

Paths reunited: initiation of the classical and lectin pathways of complement activation [PDF]

, 2010
Understanding the structural organisation and mode of action of the initiating complex of the classical pathway of complement activation (C1) has been a central goal in complement biology since its isolation almost 50 years ago.
Keeble, Anthony H., Mitchell, Daniel A., Schmid, Ralf, Schwaeble, Wilhelm J., Wallis, Russell   +4 more
core   +1 more source

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, EarlyView.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; ClinicalTrials.gov identifier ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) Network investigators   +14 more
wiley   +1 more source